2023-505985-28-01招募中2 期
An Exploratory, Multi-Centre, Interventional, Prospective, Randomised, Double-Blind, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of AON-D21 in Patients with Severe Community-Acquired Pneumonia.
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 130
- 试验地点
- 23
- 主要终点
- Frequency, severity, and relatedness to study drug of serious and non-serious treatment-emergent adverse events until Day 28.
研究概览
简要总结
To assess the safety and tolerability of AON-D21 in patients with severe CAP admitted to Intensive Care Unit (or similar unit).
研究设计
- 分配方式
- Randomized
- 主要目的
- Treatment Arms
- 盲法
- Double (Investigator, Monitor, Subject)
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- •At Screening, Randomisation and prior to administration of first dose; community-acquired pneumonia according to local guidelines. Community-acquired pneumonia may be confirmed or suspected to be of bacterial or viral origin.
- •For female participants of childbearing potential, agreement to use dual methods of contraception until Day
- •For male participants with female partners of childbearing potential, agreement to use barrier method of contraception until Day 60 and to refrain from donating sperm during the study and for 3 months after the last infusion.
- •At Screening, Randomisation and prior to administration of first dose; admitted to an Intensive Care Unit (or similar unit) defined as any hospital facility with intensive and specialised medical and nursing care, with capacity for monitoring, and physiological organ support to sustain life during a period of life-threatening organ system insufficiency.
- •At Screening, Randomisation and prior to administration of first dose: requiring respiratory support by High-Flow Oxygen ≥ 30 L/min with FiO2 ≥ 30% or Non-Invasive Mechanical Ventilation or Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation.
- •At Screening, C-reactive protein ≥ 50 mg/L. C-reactive protein measurement must be repeated and confirmed to be ≥ 50 mg/L if randomisation is not done within 24 h of Screening sample collection (local laboratory testing).
- •PaO2/FiO2 ratio ≤ 150 mmHg (≤ 20 kPa), with PaO2 from arterial blood (or arterialised capillary blood from a vasodilated ear lobe).
- •Treatment initiation no more than 48 h after initiation of respiratory support (High-Flow Oxygen ≥ 30 L/min with FiO2 ≥ 30%, Non-Invasive Mechanical Ventilation, Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation).
- •Written informed consent obtained from patient or legally designated representative or authorisation from an independent physician*, as per local guidelines. * In emergency situations, when prior consent of the participant or their legally designated representative is not possible, enrolment of the participant may be authorised by an independent physician (NON-EU Countries) or a treating physician independent of the research team (EU Countries), as per local guidelines. The participant or the participant’s legally designated representative should be informed about the trial as soon as possible, and consent should be requested.
- •Age ≥ 18 years to ≤ 85 years.
- •Body mass index ≥ 17.5 kg/m² and ≤ 40 kg/m².
排除标准
- •Refractory septic shock at Screening, Randomisation or prior to administration of the first dose of study drug. Participants can be enrolled if they are no longer refractory. The presence of refractory septic shock shall be determined by the investigator. As a guidance, septic shock may be judged as refractory if treatment with ≥ 0.5 mcg/kg/min norepinephrine or equivalent (cumulative) for at least 2 h to maintain or attempt to maintain systolic blood pressure (SBP) >90 mmHg (or mean arterial pressure (MAP) >70 mmHg) after adequate fluid resuscitation is required.
- •Not expected to survive 72 h, at Screening, Randomisation or prior to administration of first dose.
- •Hospital-acquired or ventilator-associated pneumonia or known or suspected pneumonia due to aspiration or other physical injury or trauma or tuberculosis.
- •Known fibrotic lung disease, bronchiectasis with ≥ 3 exacerbations requiring antibiotic treatment during the last year or any other known severe chronic respiratory disease (e.g., chronic obstructive pulmonary disease or cystic fibrosis) requiring home oxygen/non-invasive ventilation or with known forced expiratory volume in the first second < 30% of predicted.
- •Factors other than a pathogen suspected or confirmed to be causative for the respiratory insufficiency, e.g., clinically suspected pulmonary thromboembolism, cardiac insufficiency, including decompensated heart failure (≥ Class 3, New York Heart Association classification).
- •Active malignant disease with chemotherapy or immunomodulating cancer therapy within 30 days of screening or intended within the next 30 days or active primary lung cancer or another malignancy metastatic to the lungs or end-stage cancer.
- •Hepatocellular injury defined by an alanine aminotransferase or aspartate aminotransferase value ≥ 3 times the upper limit of normal (local laboratory). Known acute or chronic liver disease with Child-Pugh C.
- •Any medical disease (acute, subacute, intermittent, or chronic) or condition that, in the opinion of the investigator(s), compromises the participant’s safety or compromises the interpretation of the results.
- •Vasopressors, intubation, renal replacement therapy or cardiopulmonary resuscitation procedures are precluded on the basis of a patient order, next-of-kin communication or per staff decision. Clarification: The exclusion only applies when the precluded therapies or procedures result in a limitation in Standard of Care treatment escalation.
- •Applicable in France only. Persons under court protection, persons not affiliated to a social security system, protected adults (Art. L. 1121-6, Art. L. 1121-8, Art. L. 1121-8-1).
- •Receiving chronic immunosuppressive therapy in clinically relevant doses (> 15 mg/day prednisolone or equivalent as maintenance treatment for > 14 days).
- •Known immunodeficiency disease/condition (iatrogenic or congenital), including human immunodeficiency virus infection (type 1 or 2) with CD4+ counts < 200 cells/µL, asplenia, or recurrent severe infections.
- •Nursing and pregnant women (defined as the state after conception until the termination of gestation, screened in all women of child-bearing potential with a chorionic gonadotrophin blood test (local laboratory).
- •Current or recent participation in an investigational trial (within 30 days of screening, or 5 half-lives of the respective investigational compound, whichever is longer).
- •Systemic treatment with any complement inhibitor, e.g., eculizumab or avacopan.
- •Known complement deficiency.
- •Known or suspected hypersensitivity to AON-D21 or any components of the formulation used (e.g., Polyethylene Glycol, mannitol or Ethylenediaminetetraacetic Acid) or a history of clinically relevant allergy requiring continuous treatment, or of anaphylaxis.
- •Unlikely to remain at the investigational site beyond 96 hours.
结局指标
主要结局
Frequency, severity, and relatedness to study drug of serious and non-serious treatment-emergent adverse events until Day 28.
Frequency, severity, and relatedness to study drug of serious and non-serious treatment-emergent adverse events until Day 28.
次要结局
- Time to no longer requiring any organ support within 28 days.
- Time to no longer requiring respiratory support (defined as High Flow Oxygen ≥ 30 L/min with FiO2 ≥ 30%, Non-Invasive Mechanical Ventilation, Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation) within 28 days.
- Time to improvement (defined as a de-escalation in respiratory support; no oxygen support/other lower degree oxygen support < High Flow Oxygen ≥ 30 L/min with FiO2 ≥ 30% < Non-Invasive Mechanical Ventilation < Invasive Mechanical Ventilation < Extracorporeal Membrane Oxygenation) within 28 days.
- Mean change in S/F ratio from Day 1 (Baseline) to Day 7.
- Organ support-free days until Day 28.
- Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation free days until Day 28.
- Respiratory support-free days until Day 28.
- All-cause mortality up to Days 28 and 60.
- Area under the concentration-time curve (AUC) over the dosing interval at steady state (AUC0-tau), maximum concentration at steady state (Cmax), average drug concentration at steady state (Cav), trough concentrations (Ctrough), time of maximum concentration at steady state (tmax), terminal half-life at steady state (t1/2), accumulation ratios for Cmax and AUC, clearance (CL) and volume of distribution (Vz) of AON-D21 in plasma. From a subset of ≥ 20 participants from selected sites.
- Determination of C5a inhibitory activity. From a subset of ≥ 100 participants.
研究者
Functional contact point
Scientific
Aptarion Biotech AG
研究点 (23)
Loading locations...
相似试验
已完成
1 期
Safety Study of ASONEP (Sonepcizumab/LT1009) to Treat Advanced Solid TumorsSolid TumorsNCT00661414Lpath, Inc.37
已完成
1 期
ONO-7913 Phase I Study (ONO-7913)Solid TumorNCT04403308Ono Pharmaceutical Co. Ltd7
终止
1 期
Study of ONO-7579 in Patients With Advanced Solid Tumors/ NTRK Gene Fusion Positive Advanced Solid TumorsSolid TumorNCT03182257Ono Pharmaceutical Co. Ltd1
已完成
1 期
Safety and Pharmacokinetic Study of Oral ON 01910.Na in Patients With Myelodysplastic SyndromeMyelodysplastic SyndromeNCT01048619Traws Pharma, Inc.36
终止
2 期
An Open Label Safety and Tolerability Study of AIN457 in Patients With Moderate to Severe Crohn's DiseaseCrohn's DiseaseInflammatory Bowel DiseaseNCT01009281Novartis Pharmaceuticals7